<DOC>
	<DOCNO>NCT02464605</DOCNO>
	<brief_summary>This Study evaluate safety , pharmacokinetics , pharmacodynamics immunogenicity single intravenous infusion SEL-037 ( pegsiticase ) , pegylated uricase , subject elevate blood uric acid level . Uricase enzyme convert uric acid readily soluble allantoin excrete .</brief_summary>
	<brief_title>Safety Pharmacodynamics SEL-037 ( Pegsiticase ) Subjects With Elevated Blood Uric Acid Levels</brief_title>
	<detailed_description>This Study evaluate safety , pharmacokinetics , pharmacodynamics immunogenicity single intravenous infusion SEL-037 ( pegsiticase ) , pegylated uricase , subject elevate blood uric acid level . Uricase enzyme convert uric acid readily soluble allantoin excrete . Cohorts Subjects give single , ascend dose intravenous infusion SEL-037 monitor safety , uric acid level anti-drug-antibodies ( ADAs ) SEL-037 30 day .</detailed_description>
	<mesh_term>Uric Acid</mesh_term>
	<criteria>Male female subject age 21 75 inclusive . Female subject must nonchildbearing potential ; Has Screening Visit serum uric acid ≥ 6 mg/dL , without history gout ; The use allopurinol , febuxostat ( Uloric® ) , probenecid uric acidlowering therapy permissible dose stable least month prior Screening Visit Has adequate venous access able receive IV therapy ; Evidence personally sign date informed consent document indicate subject inform pertinent aspect study ; Prior exposure experimental market uricase ; History allergy pegylated product , Glucose6phosphate dehydrogenase deficiency know catalase deficiency ; History hematological autoimmune disorder , immunosuppressed immunocompromised ; Has participate clinical trial within 30 day Screening ;</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>